Valeo Pharma Inc. · OTC:VPHIF
Valeo Pharma — Investor Presentation (May 2023)
24 slides from Valeo Pharma's investor presentation, May 12, 2023
Slide 1: Corporate Presentation May 2023
Valeo Brings Innovation to Canadians, Innovation Provides Better Healthcare Corporate Presentation May 2023 (TSX: VPH) (OTCQB: VPHIF)
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Forward-Looking Statements: This presentation, including the documents incorporated by reference herein, contains “forward-looking information” as defined under Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of h
Slide 3: Overview: Who We Are
Overview WHO WE ARE WHO - Fully integrated commercial WHAT pharma Company - License/acquire HOW - Montreal Head Office Canadian rights to - 130 employees commercial stage - 12 commercialized PAGE 3 (85 Pan-Canadian sales force) prescription drugs products (6 high growth products) - TSX-OTCQB listed
Slide 4: Business Units / Therapeutic Areas
PAGE 4 BUSINESS UNITS / THERAPEUTIC AREAS 3 Business Units / 3 Therapeutic Areas Respiratory/Allergy Ophthalmology Specialty/Hospital - ENERZAIR® - XIIDRA® - REDESCA® - ATECTURA® - SIMBRINZA® - Others - ALLERJECT® TSX:VPH
Slide 5: Transformative Launches
2021-2022: Transformative Product Additions TRANSFORMATIVE LAUNCHES Revenues ($M) 160 $135M 140 120 $100M 100 PAGE 5 80 $60M + 60 40 $27.7M 20 $13.6M $7.5M 0 FY 20 A FY 21 A FY 22 A FY 23 F FY 24 F FY 25 F Spec./Hosp. Ophthalmology Respiratory VALUE PROPOSITION: TSX:VPH Significant Operating Leverag
Slide 6: Growth Potential
GROWTH POTENTIAL Diversified Portfolio: Significant Growth Potential ENERZAIR $16 M ATECTURA ALLERJECT Total Estimated Peak Sales from existing portfolio of commercial products : PAGE 6 XIIDRA $25 M $230M + SIMBRINZA REDESCA $22 M OTHERS 0 10 20 30 40 50 60 70 80 90 2023 Estimated Sales ($M) Peak Sa
Slide 7: Respiratory / Allergy Business Unit
Respiratory / Allergy Business Unit Est. 2023 Est. 2024 Est. Peak RESPIRATORY / ALLERGY Revenues Revenues Sales ($M) ($M) ($M) ENERZAIR® Asthma $90+ ATECTURA® Asthma $16M $40M $30+ ALLERJECT® Allergy $25+ $145
Slide 8: Asthma: Canadian Market Dynamics
Asthma: Canadian Market Dynamics ASTHMA: CANADIAN DYNAMICS ➢ 3.8 million Canadian asthma sufferers ➢ 1 million Targeted Patient SINGLE agent Population (moderate to severe) (CorticosteroidS) ➢ 50% of asthma sufferers with poor symptoms control DUAL agents PAGE 8 (Corticosteroids + Bronchodilator) *$
Slide 9: Enerzair & Atectura Breezhaler
ENERZAIR / ATECTURA ENERZAIR & ATECTURA BREEZHALER Enerzair Atectura Launched Q4-21, Q4-21, First in Class Best in Class Target Market 350k Patients 615K Patients Triple Agent Therapy Peak Sales $80M $25M triple combination ICS/LABA/LAMA PAGE 9 % of Patients @ Peak 43% 14 % Key Clinical Data 42% red
Slide 10: Enerzair / Atectura: Prescription Trends (Mar. 2023)
Enerzair / Atectura: Prescription Trends (Mar. 2023) Total # of Prescribers 1,889 Total # of Prescriptions 41,329 1,800 1,724 40,000 37,508 1,583 472 33,920 1,600 35,000 32,899 1,429 445 1,400 1,284 420 30,000 28,253 22,868 1,136 394 20,730 1,200 24,024 1,004 25,000 370 17,69118,705 1,000 883 20,201
Slide 11: Allerject
ALLERJECT Allergy/Severe Reactions: ALLERJECT® Features Epipen Allerject (Market leader) Annual Revenues $75-80M $4-5M Pricing $95-105 Same Reimbursement 75% coverage Same Voice assisted No Yes PAGE 11 FDA Guidance for Device N.A. First to meet 99.999% Reliability User Friendly Average Yes Pocket si
Slide 12: Ophthalmology Business Unit
Ophthalmology Business Unit Est. 2023 Est. 2024 Est. Peak Ophthalmology Revenues Revenues Sales ($M) ($M) ($M) Dry eye XIIDRA® $25M $33M $30+ disease SIMBRINZA® Glaucoma $15+ $45
Slide 13: Xiidra / Simbrinza
XIIDRA®: Dry Eye Disease SIMBRINZA®: Glaucoma XIIDRA/SIMBRINZA PAGE 13 Target Market: Target Market: - 8M people, 2% treated with Rx - 400,000 Canadians - 1,200 Ophthalmologists - 1,200 Ophthalmologists Current Mkt Share: 24% Current Mkt Share: 18% Mkt Size: ~$80M Primary Mkt Size: ~$60M Mkt CAGR: 5
Slide 14: Xiidra & Simbrinza Revenues
XIIDRA & SIMBRINZA REVENUES XIIDRA® – SIMBRINZA® Revenues Valeo acquires PEAK SALES 50,000,000 commercial rights ~$45m (July 22) 40,000,000 30,000,000 PAGE 14 20,000,000 10,000,000 0 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 XIIDRA Net TO SIMBRINZA Net TO Xiidra: “Unpromoted” since 2021
Slide 15: Specialty Products Business Unit
Specialty Products Business Unit Est. 2023 Est. 2024 Est. Peak Specialty Products Revenues Revenues Sales ($M) ($M) ($M) REDESCA® Blood Thinner $22M $27M $25+ Pain, Parkinson, OTHERS® $15+ Oncology $40
Slide 16: Redesca
REDESCA Redesca® (Biosimilar) LMWH Biosimilar Market insight: March.-23 Monthly - IQVIA 100% 90% 80% 70% 60% Redesca – Market share Leader PAGE 16 REDESCA 50% INCLUNOX NOROMBY 40% 30% 20% 10% 0% Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22
Slide 17: Financials & Summary
Financials & Summary
Slide 18: P&L Improvements
P&L IMPROVEMENTS Sequential P&L Improvement 20 Quarterly Performance 20 Q1-23 VS. Q1-22 15 15 • 5th Qtr of revenue growth - up 210% • 5th Qtr of Adj. Gross Profit - up 178% 10 10 • 5th Qtr of A.EBITDA loss reduction – down 51% PAGE 18 $ Millions 5 5 2023 • Current Revenues run rate: $52M + • Revenue
Slide 19: Capital Structure
Capital Structure, as at May 12, 2023 CAPITAL STRUCTURE CAPITALIZATION MILLIONS Shares Outstanding (Share Price - $0.44) 84.2 Options/RSUs (avg. price, $0.62) 7.9 Warrants (avg. strike price $1.19) 15.6 Management & Insiders Convertible debentures ($25.0M) 21.7 aligned with shareholders. PAGE 19 Ful
Slide 20: Business Development & Partners
BUSINESS DEVELOPMENT Business Development & Partners Respiratory: Ophthalmology: Specialty/Hospital: - ENERZAIR®: Novartis - XIIDRA®: Novartis Spec. Products: - ATECTURA®: Novartis - SIMBRINZA®: Novartis - REDESCA®: Shenzhen Techdow PAGE 20 - M-ESLON®: Ethypharm Allergy: - ALLERJECT®: Kaléo Neurolog
Slide 21: 2023 Upcoming Milestones
2023 Upcoming milestones UPCOMING MILESTONES Date Milestones Q4-23 • Adjusted EBITDA break-even FY-23 • Licensing of additional Canadian rights to commercial products PAGE 21 FY-23 • >100% Revenue Growth TSX:VPH
Slide 22: Leadership Team
Leadership LEADERSHIP TEAM MANAGEMENT BOARD Steve Saviuk Richard J. MacKay Maureen C. Brennan Founder, CEO Chairman Board Member Founder and CEO Since 2003 Former Vice-Chairman 40+ years in private and of Stiefel Laboratories public health sector Former Director General Luc Mainville Steve Saviuk Sh
Slide 23: Investment Summary
Investment Summary INVESTMENT SUMMARY • Leading topline growth 2023, and beyond • Commercial focus (no R&D / clinical trials) • 6 growth assets launched/acquired last 2 yrs. PAGE 23 • Peak sales potential ≥ $230M • Significant operating leveraging • Active BD&L efforts for additional product TSX:VPH
Slide 24: Contact Us
Contact Us PHONE 514-694-0150 EMAIL ir@valeopharma.com WEB www.valeopharma.com